Multidrug resistance in brain tumors: Roles of the blood-brain barrier

Cancer and Metastasis Reviews

Volumn 20, Issue 1-2, 2001, Pages 13-25

  Régina, Anthony ^a   Demeule, Michel ^a   Laplante, Alain ^a   Jodoin, Julie ^a   Dagenais, Claude ^a   Berthelet, France ^b   Moghrabi, Albert ^a   Béliveau, Richard ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

Blood brain barrier; Brain tumors; Endothelial cells; Multidrug resistance; P glycoprotein

Indexed keywords

ANGIOGENESIS INHIBITOR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CENTRAL NERVOUS SYSTEM; ENDOTHELIUM CELL; HUMAN; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN;

EID: 0035692282     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013104423154     Document Type: Article

References (89)

1. The response of cerebral metastases in small cell lung cancer to systemic chemotherapy
2. Kinetic and biochemical analysis of cartier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: Importance in the drug delivery to the brain
3. Cartier-mediated or specialized transport of drugs across the blood-brain barrier
4. Vector-mediated drug delivery to the brain
5. Determinants of passive drug entry into the central nervous system
6. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier
7. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins
8. Reduced permeability in CHO cells as a mechanism of resistance to colchicine
9. P-glycoprotein: Its role in drug resistance
10. Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine
11. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells
12. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities
13. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
14. Expression of a multidrug-resistance gene in human tumors and tissues
15. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues
16. Isoform I (mdr3) is the major form of P-glycoprotein expressed in mouse brain capillaries. Evidence for cross-reactivity of antibody C 219 with an unrelated protein
17. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells
18. Isolation of endothelial cells from brain, lung, and kidney: Expression of the multidrug resistance P-glycoprotein isoforms
19. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain
20. Cellular localization of P-glycoprotein in brain versus gonadal capillaries
21. Specialized localization of P-glycoprotein recognized by MRK 16 monoclonal antibody in endothelial cells of the brain and the spinal cord
22. Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain
23. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells
24. Up-regulation of caveolin-1 and caveolae organelles in taxol-resistant A549 cells
25. P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries
26. Role of plasmalemmal caveolae in signal transduction
27. Filipin-sensitive caveolae-mediated transport in endothelium: Reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules
28. Endocytosis and transcytosis
29. Caveolin is an activator of insulin receptor signaling
30. P-glycoprotein, a gatekeeper in the blood-brain barrier
31. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
32. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines
33. Localization of a novel multidrug resistance-associated associated in the HT1080/DR4 and H69AR human tumor cell lines
34. The multidrug resistance protein family
35. Tissue distribution of the multidrug resistance protein
36. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage
37. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung
38. Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus
39. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells
40. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line
41. Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro
42. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates
43. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells
44. A family of drug transporters: The multidrug resistance-associated proteins
45. MRP3, an organic anion transporter able to transport anti-cancer drugs
46. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2
47. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors
48. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme
49. Ultrastructure of capillary walls in human brain tumors
50. Immunohistochemical study of tight junction-related protein in neovasculature in astrocytic tumor
51. Ultrastructural and morphometric investigation of human brain capillaries in normal and peritumoral tissues
52. Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma?
53. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance
54. Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes
55. The multidrug-resistance gene MDR1 is expressed in human glial tumors
56. P-glycoprotein expression in brain tumors
57. Multidrug resistance gene (MDR1) expression in human brain tumors
58. Reversal of chemoresistance in malignant gliomas by calcium antagonists: Correlation with the expression of multidrug-resistant P-glycoprotein
59. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors
60. Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens
61. Comparative assessment of P-glycoprotein in mammalian tissues by immunoblotting
62. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors
63. Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein
64. Mdr1 mRNA expression differs between grade III astrocytomas and glioblastomas
65. Expression of the multidrug-resistance P-glycoprotein (P-gp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors
66. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines
67. Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells
68. Expression of multidrug resistance-associated protein (MRP) in human gliomas
69. Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma
70. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats
71. Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro
72. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
73. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic
74. Phase I/II study of the P-glycoprotein modulator PSC833 in patients with acute myeloid leukemia
75. Osmotic opening of the blood-brain barrier: Principles, mechanism, and therapeutic applications
76. Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy
77. Enhanced delivery of carboplatin into brain tumours with intravenous cereport (RMP-7): Dramatic differences and insight gained from dosing parameters
78. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma
79. Targeted drug delivery to the brain (blood-brain barrier, efflux, endothelium, biological transport)
80. Matrix metalloproteinases: Biologic activity and clinical implications
81. Matrix proteinase inhibition by AE- 941, a multifunctional antiangiogenic compound
82. AE-941 (Neovastat) shows a beneficial effect in experimental glioma and is associated with high angiostatin level in treated tumors
83. Genes expressed in human tumor endothelium
84. Inhibitory effect of epigallocatechin-gallate on brain tumor cell lines in vitro
85. Matrix metalloproteinase inhibition by green tea catechins
86. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols
87. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation
88. The glucose transporter and blood-brain barrier of human brain tumors
89. Selective lutheran glycoprotein gene expression at the blood-brain barrier in normal brain and in human brain tumors